Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT01984242

Public ClinicalTrials.gov record NCT01984242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Study identification

NCT ID
NCT01984242
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
305 participants

Conditions and interventions

Interventions

  • Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody Drug
  • Bevacizumab Drug
  • Sunitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 7, 2014
Primary completion
Oct 16, 2016
Completion
Jan 7, 2019
Last update posted
Dec 22, 2019

2014 – 2019

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
HonorHealth Research Institute - Bisgrove Scottsdale Arizona 85258
City of Hope Comprehensive Cancer Center Duarte California 91010
UCLA Los Angeles California 90024
University of California San Francisco California 94158
Univ Colorado Health Sci Ctr Aurora Colorado 80045
Rocky Mountain Cancer Ctr - Denver (Williams) Denver Colorado 80218
Yale Uni School of Medicine; Section of Medical Oncology New Haven Connecticut 06510-3289
Georgetown U; Lombardi Comp Can Washington D.C. District of Columbia 20016-1468
SCRI Florida Cancer Specialists South Fort Myers Florida 33916
Mayo Clinic-Jacksonville Jacksonville Florida 32224
Florida Cancer Specialist, North Region St. Petersburg Florida 33705
The University of Chicago Chicago Illinois 60637
Massachusetts General Hospital Boston Massachusetts 02114
Dana Farber Cancer Inst. Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Karmanos Cancer Institute. Detroit Michigan 48201
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89128
Memorial Sloan-Kettering New York New York
Oncology Hematology Care Inc Cincinnati Ohio 45242
Cleveland Clinic Foundation; Taussig Cancer Center Cleveland Ohio 44195
Oncology Associates of Oregon, P.C Eugene Oregon 97401
Northwest Cancer Specialists, P.C. Tigard Oregon 97223
Tennessee Oncology PLLC - Nashville (20th Ave) Nashville Tennessee 37203
Vanderbilt Medical Center Nashville Tennessee 37232-7610
Texas Oncology-Baylor Sammons Cancer Center Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01984242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2019 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01984242 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →